Role of Tenecteplase in Myocardial Infarction Management

Primary Reperfusion Strategy

The European Society of Cardiology recommends primary PCI as the preferred reperfusion strategy for STEMI when it can be performed by an experienced team within 90-120 minutes of STEMI diagnosis 1, 2
When primary PCI cannot be performed in a timely manner, the American Heart Association recommends fibrinolytic therapy should be initiated as soon as possible, preferably in the pre-hospital setting 1, 3
The European Society of Cardiology recommends a fibrin-specific agent (tenecteplase, alteplase, or reteplase) over non-fibrin-specific agents 1, 3

The American College of Cardiology recommends tenecteplase administration as a single weight-adjusted intravenous bolus, with dosing as follows:
For patients ≥75 years old, the European Society of Cardiology recommends a 50% dose reduction to reduce stroke risk 2

The American Heart Association recommends oral or IV aspirin (150-325 mg) should be administered immediately 1, 3
The European Society of Cardiology recommends clopidogrel should be added to aspirin 1, 2
The European Society of Cardiology recommends anticoagulation should be administered until revascularization or for the duration of hospital stay (up to 8 days) 1, 4
The European Society of Cardiology recommends enoxaparin IV followed by subcutaneous (preferred over unfractionated heparin) 1, 4
The European Society of Cardiology recommends unfractionated heparin as weight-adjusted IV bolus followed by infusion 1

The European Society of Cardiology recommends transfer to a PCI-capable center following fibrinolysis is indicated in all patients immediately after fibrinolysis 1
The American Heart Association recommends rescue PCI is indicated immediately when fibrinolysis has failed (<50% ST-segment resolution at 60-90 minutes) or in the presence of hemodynamic or electrical instability 1, 5
The European Society of Cardiology recommends angiography and PCI of the infarct-related artery is recommended between 2-24 hours after successful fibrinolysis 1, 5

The European Society of Cardiology recommends tenecteplase is particularly beneficial in patients presenting late (>4 hours after symptom onset) due to its higher fibrin specificity 6
The American College of Cardiology recommends tenecteplase is contraindicated in patients with prior intracranial hemorrhage, known structural cerebral vascular lesion, ischemic stroke within 3 months, suspected aortic dissection, active bleeding, or significant closed-head trauma within 3 months 3
The European Society of Cardiology recommends for patients in cardiogenic shock, primary PCI remains the preferred strategy over fibrinolytic therapy 1, 2

The American College of Cardiology recommends immediate PCI following tenecteplase administration, with a significant reduction in the composite endpoint of death, reinfarction, recurrent ischemia, heart failure, and cardiogenic shock from 17.2% to 11.0% (RR 0.64, p=0.004) in patients with ST-segment elevation myocardial infarction 7, 8
The American College of Cardiology suggests that transfer to a PCI center should be initiated immediately after fibrinolysis without waiting to determine whether reperfusion has occurred, with a median time from tenecteplase to catheterization of approximately 2.8 hours 8, 9
The American Heart Association recommends that coronary angiography and PCI of the infarct-related artery should be performed between 2-24 hours after tenecteplase administration in patients with successful fibrinolysis, reducing mortality by 38% and reinfarction by 41% compared to delayed or ischemia-driven PCI 9

The American College of Cardiology recommends performing rescue PCI immediately if signs of failed reperfusion are present, including persistent chest pain, <50% ST-segment resolution at 60-90 minutes, or hemodynamic/electrical instability 9

The American College of Cardiology recommends continuing aspirin and clopidogrel (or other P2Y12 inhibitor) during transfer, as well as maintaining anticoagulation with unfractionated heparin or enoxaparin until revascularization 7, 8

The American College of Cardiology identifies high-risk features that warrant an aggressive approach, including ≥2 mm ST-elevation in 2 anterior leads, systolic blood pressure <100 mmHg, heart rate >100 bpm, Killip class II-III, ≥2 mm ST-depression in anterior leads, and right ventricular involvement 7, 8

The American College of Cardiology notes that while the pharmacoinvasive strategy increases GUSTO mild bleeding (13.0% vs 9.0%), there is no significant difference in TIMI major/minor bleeding or GUSTO moderate/severe bleeding compared to standard treatment 7, 8